Promising leukemia drug fails to finish trial for kids with stubborn disease
NCT ID NCT03913559
First seen Feb 05, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This study tested a drug called inotuzumab ozogamicin (Besponsa) in children and young adults with a type of leukemia (B-ALL) that still had small amounts of cancer cells after standard treatment. The goal was to see if the drug could make those leftover cells disappear. Only 5 people enrolled before the study was stopped early. The drug targets a protein called CD22 found on most leukemia cells and delivers a strong chemotherapy directly to them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rady Children's Hospital San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.